# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
While in orbit, the Polaris Dawn crew will conduct scientific research designed to advance both human health on Earth and our u...
Royal Caribbean has "the best systems right now," Jim Cramer says. "It's got the best numbers. It's the one...
Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and maintains $90 price target.
DexCom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor, is now available without a ...
Available for purchase today at Stelo.com for people in the U.S. 18 and older not using insulinProvides 24/7 powerful and perso...
Stifel analyst Mathew Blackman maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $100.